Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In a new study published in journal Scientific Reports, scientists at NDORMS and Queen Mary University of London have identified reasons underpinning the failure of inflammation to resolve in disorders of musculoskeletal soft tissues such as tendons.

Tendinopathy is a common global disease burden, causing pain and disability. These injuries require prolonged convalescence and there are currently no effective treatments. In the study by Dakin et al. the authors investigated why tendon inflammation fails to resolve in some patients with chronic disease. They studied profiles of pro-inflammatory and inflammation resolving lipids in tendon stromal fibroblasts isolated from patients with tendinopathy and compared them with those derived from healthy donors. Cells from patients with tendinopathy displayed a pro-inflammatory profile and dysregulated resolution responses compared to cells isolated from healthy volunteers. Incubating tendon stromal cells in tissue protective pro-resolving compounds including the aspirin stable isoform 15-epi-LXA4 induced the production of other proresolving lipid mediators and moderated the pro-inflammatory phenotype of diseased tendon stromal cells.

 The investigators noted that the effects of 15-epi-LXA4 treatment were more profound in healthy compared to diseased tendon stromal cells. They identified that cells from tendinopathy patients displayed enhanced ability to convert proresolving mediators to metabolites that carry reduced biological actions. Diseased tendon tissues and cells highly expressed an enzyme (15-PGDH) implicated in the inactivation of tissue protective proresolving mediators. Inhibition of 15-PGDH significantly reduced the further conversion of proresolving mediators and moderated the inflammatory phenotype of diseased tendon cells. These findings suggest that chronic inflammation in musculoskeletal soft tissues may result from dysregulated resolution responses. The authors propose that a dual pronged approach, using pro-resolving mediators together with inhibitors to 15-PGDH represents a novel therapeutic strategy to reduce local tendon inflammation and promote tissue repair. 

Figure 1

Spectra identifying the further metabolites of pro-resolving mediators in tendon stromal cells isolated from healthy volunteers (HV) and patients with tendon disease (TD). Cells from tendinopathy patients displayed enhanced ability to convert tissue protective proresolving mediators to metabolites that carry reduced biological actions. Staining shows cells from patients with tendinopathy highly express 15-PGDH, implicated in the inactivation of proresolving mediators.

Spectra-identifying-the-further-metabolites-of-pro-resolving-mediators.png

read THE FULL STUDY on Scientific Report:

Increased 15-PGDH expression leads to dysregulated resolution responses in stromal cells from patients with chronic tendinopathy. Stephanie G Dakin, Lucy Ly, Romain A. Colas, Udo Oppermann, Kim Wheway, Bridget Watkins, Jesmond Dalli, Andrew J Carr.

 

 

 

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.